This study is looking at whether the drug azacitidine can help patients with myeloid malignancies (cancers of the blood and bone marrow) like AML or MDS after they've had an allogeneic stem cell transplant (a transplant using donor cells). Sometimes after a transplant, the donor cells (chimerism) might decrease, which can increase the risk of the cancer coming back. Researchers want to see if azacitidine can help keep the donor cells stable and reduce the chance of relapse, without causing more graft-versus-host disease (when donor cells attack the patient's body). You might be able to join if you are between 18 and 75 years old and have experienced a drop in your donor cells after your transplant, or if your donor cells are below 98% without the cancer returning. The study aims to enroll 43 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 43 participants.

What's involved

You would receive azacitidine at 32mg/m2 for 5 days every 28 days, for at least 4 cycles if you tolerate it well.

Compensation

Not stated in the trial record.

Follow-up

The main goal is to measure the rate of increase or stable donor chimerism at one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.